CN1358534A - Compound medicine for treating bronchial asthma and preparation process - Google Patents

Compound medicine for treating bronchial asthma and preparation process Download PDF

Info

Publication number
CN1358534A
CN1358534A CN 01135286 CN01135286A CN1358534A CN 1358534 A CN1358534 A CN 1358534A CN 01135286 CN01135286 CN 01135286 CN 01135286 A CN01135286 A CN 01135286A CN 1358534 A CN1358534 A CN 1358534A
Authority
CN
China
Prior art keywords
bronchial asthma
medicine
treatment
asthma
aminophylline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 01135286
Other languages
Chinese (zh)
Inventor
王志强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN 01135286 priority Critical patent/CN1358534A/en
Publication of CN1358534A publication Critical patent/CN1358534A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention discloses a compound medicine for curing bronchial asthma prepared by using several medicine. It is made up dioxypromazine, clenbuterol, aminophylline, asparagus, tussilago, licorice and chlotrimeton according to a certain mixing ratio. Its preparation method includes the following steps: soaking asparagus, tussilago and licorice, decocting and filtering to obtain liquid medicine, concentrating and fully mixing it with the raw materials of dioxypromaxine, clenbuterol, aminophylline and chlotrimeton, drying and making it into capsule or talbet with a certain weight. Said invention is obvious in therapeutic effect, and high in cure rate, can be extensively used for curing bronchial asthma.

Description

A kind of compound medicine for the treatment of bronchial asthma and preparation method thereof
The present invention relates to a kind of medicine for the treatment of bronchial asthma and preparation method thereof, specifically a kind of is the compound medicine and preparation method thereof of the treatment bronchial asthma that forms of preparation of raw material by multiple medications.
Bronchial asthma is a kind of a kind of bronchus reflection property enhancing that causes because of anaphylactogen or other factors, cause bronchial muscular spasm, mucosa swelling, secretions increases, the bronchus tube chamber is narrow, it is the disease of feature that ictal dyspnea and asthmatic breath sounds are arranged clinically, and morbidity season is mainly in autumn and winter, and take second place spring.Primary disease shows effect repeatedly, and delay is difficult, and particularly the morbidity of north cold area and middle-aged and elderly people is very general and serious, and patient's physical and mental health is brought very big harm.Modern medicine study thinks that irritated and autonomic nervous dysfunction is two principal elements of bronchial asthma morbidity, and the outbreak repeatedly of bronchial asthma is caused by many risk factors, the one, and respiratory tract infection.Mainly cause, as rhinovirus, respiratory syncytial virus, influenza virus etc. by virus.The patient due to illness substance allergy or inflammatory stimulus fan compose oneself through, infect making bronchial mucosa inflammation edema, cellular infiltration and secretions increase, increase the weight of asthma; The 2nd, anaphylactogen and chemical factors.Can be after patient's contact allergy is former by the morbidity of anaphylaxis factor pathogeny, some nonantigenic chemical factors are as sucking cold air, dust, atmospheric pollution, smoking even cooking gas, stimulate intrabronchial sensor, excited vagus causes asthma attack; The 3rd, function of five internal organs weakens.Strain, decline cause heart blood supply not strong, deficiency of heart-QI, and lung expansion slows down, the taste QI-mass water that stagnates, defecation is not smooth, and the vivotoxin poisonous substance can not in time be discharged, initiation asthma; The 4th, climate change.Frequent and the many cataclysms of autumn and winter climate change, easy ill toxicity upper respiratory tract infection, air pressure is low can to make pollen, harmfulness dust, irritative gas etc. be gathered in ground, and concentration increases, and sucks easily, all can bring out asthma; The 5th, Nervous and Mental Factors.Excited, trained reflex all can bring out bronchial asthma.
At present, a lot of to the THE TREATMENT OF BRONCHIAL ASTHMA method both at home and abroad.Its Therapeutic Principle removes the cause of disease, control of seizures and prevention of recurrence.Aspect control of seizures, to light, moderate outbreak, mainly be to carry out bronchus with theophylline class medicine such as aminophylline, adrenin such as salbutamol, adrenal cortex saccharide hormone etc. to separate stem, eliminate the phlegm, use the antibiotic medicine control infection with medicines such as ammonium chloride, potassium iodide; Asthma is continued the outbreak state, mainly is to rely on oxygen uptake, intravenous drip aminophylline, hydrocortisone, antibiotic etc. to treat.Aspect prevention of recurrence, mainly be to take disodium cromoglycate, injection asthmatic vaccine or nuclear cheese and adopt desensitization therapy etc.Domestic also a small amount of in addition treatment by Chinese herbs bronchial asthma that adopts.But existing therapy exists, and therapeutic effect is undesirable, easily outbreak repeatedly, toxic and side effects is big, treatment time is long, therapeutic process is complicated, the patient is to shortcomings such as drug dependence are strong, does not reach the curative effect of thorough healing bronchial asthma.
Purpose of the present invention just is to provide that a kind of therapeutic effect is remarkable, cure rate is high, the compound medicine of the treatment bronchial asthma of non-evident effect, instant effect, nothing recurrence, taking convenience.
The present invention is achieved in that
A kind of compound medicine for the treatment of bronchial asthma, it is that various composition medicines by the following weight proportioning are the medicine that raw material is made, wherein:
Dioxopromethazine: 3-12 part; Clenbuterol: 0.02-0.08 part; Aminophylline: 50-400 part; Radix Asparagi: 5000-30000 part; Flos Farfarae: 5000-30000 part; Radix Glycyrrhizae: 5000-15000 part; Chlorphenamine: 2-6 part.
The best by weight enforcement proportioning of medicine of the present invention is: get 10 parts in dioxopromethazine, 0.04 part of clenbuterol, 200 parts of aminophyllines, 14000 parts of Radix Asparagi, 16000 parts of Flos Farfaraees, 8000 parts in Radix Glycyrrhizae, 4 parts of chlorphenamines.BATIANMEN winter, Flos Farfarae, Radix Glycyrrhizae soak, decoct and filtering residue after medicinal liquid concentrate, then with the abundant combination dryings of crude drug such as dioxopromethazine, clenbuterol, aminophylline, chlorphenamine after, be made into 260 milligrams every the capsule or the tabloid of constant weight.Each 2 or several pieces during use, every day three times, 14 days is a course of treatment, serve on two courses of treatment, can effectively treat bronchial asthma.
It is bronchial muscular spasm and the pathogenetic understanding and the Therapeutic Principle that cause to bronchial asthma morbidity that solution of the present invention is based on modern medicine study, find with reference to modern medicine study, select to contain the Western medicine of various active ingredients and Chinese herbal medicine extract and formed compound medicine, comprehensively play bronchus spasmolysis, eliminate the phlegm, control infection, prevention of recurrence and alleviate respiratory tract infection, anaphylactogen, chemical factors, climate change, Nervous and Mental Factors etc. to the bringing out of bronchial asthma, thereby reach the purpose of treatment, control and prevention bronchial asthma attack.
Modern pharmacology studies have shown that:
1, dioxopromethazine.This product is the derivant of promethazine, has stronger central antitussive effect and relieving asthma to eliminate the phlegm antihistamine, local anesthesia, releasing smooth muscle spasm and antiinflammation.Can cooperate other medicines treatment bronchial asthma.
2, clenbuterol.This product acts on the beta 2 receptor of bronchial smooth muscle and strengthens ciliary movement, and the promotion sputum is discharged and relievingd asthma.Can cooperate other medicines treatment bronchial asthma.
3, aminophylline.Aminophylline is the complex of theophylline and ethylenediamine, and it can destroy the phosphodiesterase of phosphoric acid gland glycoside (CAMP) by inhibition, thereby increases the content of CAMP in cell, and makes the sliding muscle relaxation of bronchus sheep.Alleviations such as mainly curing bronchial asthma, asthmatic bronchitis, the obstructive emphysema symptom of panting.Also can be used for treating the asthma of heart failure.
4, Flos Farfarae.Dry flower for the feverfew coltsfoot.Acrid in the mouth, little sweet, warm in nature, return lung meridian.Nourishing the lung to keep the adverse QI downward, preventing phlegm from forming and stopping coughing.Cure mainly that new chronic cough is coughed, asthma, abundant expectoration, chronic cough spitting of blood etc.
Modern medicine study proves: Flos Farfarae contains alkaloid (Flos Farfarae alkali etc.), coltsfoot alcohol, plant sterol, tarachrome, tannin, aminoacid and inorganic elements etc.Pharmacological research shows that this product has antitussive, eliminates the phlegm, relievings asthma, breathes excited, the effect of antiplatelet activity factor, the effect that rises blood pressure in addition in addition.
5, Radix Asparagi.Tuber for the liliaceous plant Radix Asparagi.Sweet in the mouth, hardship, property Great Cold.Return lung, kidney channel.Lung heat clearing pathogenic fire reducing, nourshing Yin and drynsessmoistening prescription.Cure mainly fever due to yin deficiency, the cough haematemesis, consumptive lung disease, lung abscess, laryngopharynx swelling and pain, quench one's thirst, constipation.
Modern medicine study proves: Radix Asparagi contains asparagine (agedoite), is stained with liquid matter, cupreol, 5-methoxy furfural and steroid saponin.Pharmacological research shows that this product has stronger antibacterial action, the decoct in vitro tests, and anthrax bacillus, first type and hemolytic master are connected coccus, Diplococcus pneumoniae, staphylococcus aureus, bacillus albus, bacillus subtilis, bacillus pyocyaneus etc. inhibitory action.Contained Radix Asparagi have cough-relieving, antiasthmatic effect; Cupreol has antitussive, phlegm-dispelling functions.
6, Radix Glycyrrhizae extract (Chinese herbal medicine).Property is put down, and sweet in the mouth is nontoxic.Can promote the usefulness of other medicines, remove toxin in the medicine, relieving convulsion, refresh oneself expelling phlegm for arresting cough.
7, chlorphenamine.This product is applicable to the antihistaminic symptom.As: urticaria, contracting property of blood vessel neighbour rhinitis, vasodilation, pollinosis, contact dermatitis and because caused allergic conditions such as insect bite stimulation, drug reaction or food.
In sum, in the medicine of the present invention, Chinese medicinal ingredients has antiinflammatory, antiallergic action and antibiotic, spasmolytic, relaxing smooth muscle effect, and western medicine composition can be alleviated bronchial muscular spasm and bronchial mucosa congestion and edema, the bronchus bore is enlarged, remove asthma.Medicine Chinese medicine and western medicine of the present invention combination has the antiinflammatory spasmolytic, an effect such as eliminate the phlegm of relievining asthma.Effect is all multifactor comprehensive functions to medicine of the present invention to THE TREATMENT OF BRONCHIAL ASTHMA, at the pathogeny of bronchial asthma, by different action pathway, comprehensively brings into play the length of each pharmaceutical compositions, reaches treating both the principal and secondary aspects of a disease, eliminates the purpose of bronchial asthma attack.
Clinical drug of the present invention uses the result to show that following advantage is arranged:
1, to select clinical single-dose thing commonly used and Chinese herbal medicine for use be raw material in the present invention, and each component maximum level is no more than the pharmacopeia regulation, and is safe in utilization, and do not have incompatibility, scientific formulation each other.Utilize the comprehensive function treatment bronchial asthma of multiple single-dose and Chinese herbal medicine, useful effect is coordinated and non-evident effect mutually, and with low cost.
2, the present invention has avoided the infringement to human body such as non-steroidal drug, and is safe and reliable, taking convenience.
3, medicine of the present invention can use separately, also can cooperate at patient's state of an illness and take other drug; Can effectively increase medicine power of the present invention, improve patient's mental status, improve the quality of living.
4, the total effective rate of medicine of the present invention reaches more than 94.8%.
5, to the bronchial asthma patient of Drug therapy of the present invention, follow up a case by regular visits to 1-3, do not have any recurrence.
For showing medicine of the present invention to the THE TREATMENT OF BRONCHIAL ASTHMA effect, medicine of the present invention and routine medication bronchial asthma have been carried out the clinical treatment contrast test, it specifically tests as follows.
Diagnostic criteria: bronchial asthma is divided three kinds of exogenous (anaphylactic type asthma), endogenous (infection type asthma) and Combination.Premonitory symptoms such as cough, uncomfortable in chest or continuous sneeze are often arranged before the outbreak.Dyspnea, asthma and excessive phlegm appear in stage of attack, physical examination, and much fuller chest is, and chest wall movement is limited, and percussion is hyperresonant note, and border of cardiac dullness dwindles, and liver dullness circle moves down, and auscultation two lungs are covered with the asthma sound.Outbreak later stage accompanying infection person can have moist rale, and purple water from washing rice appears in severe patient.The outbreak persistent state, dyspnea increases the weight of, and mouth breathing, purple water from washing rice, dripping sweat, pale complexion appear, the extremity fault is cold, pulsation is fast, respiratory failure occurs when serious, auscultation has obvious wheezing sound.
Test grouping: choose complete data patient 169 examples before and after the treatment, all cases all meet above-mentioned bronchial asthma diagnostic criteria, selected case age 11-62 year, average 42.5 years old, medical history 0.5~19 year, average 8.6 years.By age, sex, medical history, the state of an illness, be divided into medication therapy groups of the present invention and conventional medicine matched group at random, wherein 96 examples are organized in treatment, matched group 73 examples, two groups of various diagnostic observation indexs relatively all do not have significant difference.
Therapeutic Method: medication therapy groups of the present invention is taken 260 milligrams/of medicine capsules of the present invention (or tablet of constant weight), each 2 or several pieces, and every day 3 times, 14 days is a course of treatment.After taking a course of treatment, the pulmonary respiration amount increases, and blood pressure is normal substantially, and sleep is better, and appetite is preferable; Expectorant, breathe heavily, cough disease and disappear substantially.Obey a course of treatment again, various transference cures do not have recurrence substantially.
The routine medication matched group is taken aminophylline 0.1-0.2g/ time, and every day 3 times, 14 days is a course of treatment, takes two courses of treatment continuously.
Curative effect determinate standard: finish back or the disappearance of drug administration process mesobronchus asthma two courses of treatment, and no recidivist is for curing in 3 months; If the recurrence of 3 months entobronchus asthma, take again after a course of treatment bronchial asthma promptly disappearance person be produce effects; After finished two courses of treatment, bronchial asthma alleviated or disappears, when being arranged, inducement easily shows effect, but the attack times minimizing, the persistent period shortens and does not influence work and give birth to the reviver for effective; After finishing two courses of treatment, do not alleviate but still show effect frequently though bronchial asthma has to alleviate or have, and to influence work and give birth to the reviver be invalid.
Therapeutic outcome: in the treatment group, cure 29 examples, account for 30.2%; Produce effects 41 examples account for 42.7%; Effective 21 examples account for 21.9%; Invalid 5 examples account for 5.2%; Total effective rate 94.8%.In the matched group, cure 14 examples, account for 19.2%; Produce effects 22 examples account for 30%; Effective 12 examples account for 16.4%; Invalid 2.25 examples account for 34.2%, total effective rate 65.8%.
Picked at random 4 examples are described further effect of drugs of the present invention from above-mentioned test.
Example 1: Xing Liansheng, the man, 62 years old, Heilongjiang Province's huge rock people from county, cough, asthma are more than 3 years, and see the doctor for treatment in many places, i.e. slowly recurrence after the drug withdrawal.Take medicine of the present invention after two courses of treatment, after drug withdrawal in May, 2000, recurrence so far.
Example 2: Zhang Guanghou, the man, 57 years old, Yanggu County ten Wu Liyuan people from town suffered from uncomfortable in chest, cough, asthma, and inappetence, weak all over was had a surplus in 2 years, took medicine of the present invention after two courses of treatment, and above-mentioned symptom all disappears, after drug withdrawal in October, 2000, recurrence so far.
Example 3: Zhu Li, the woman, 26 years old, Taiqian County grandson's mouth village people suffered from bronchial asthma 8 years, took medicine of the present invention and fully recovered after two courses of treatment, followed up a case by regular visits to not recurrence in 3 years.
Example 4: Yang Fenghua, the woman, 46 years old, Acheng, Yanggu County people from town suffered from bronchial asthma 4 years, took medicine of the present invention after two courses of treatment, and transference cure is followed up a case by regular visits to and was not had recurrence in 2 years.

Claims (3)

1, a kind of compound medicine for the treatment of bronchial asthma is characterized in that: it is that various composition medicines by the following weight proportioning are the compound medicine that raw material is made.
Dioxopromethazine: 3-12 part; Clenbuterol: 0.02-0.08 part; Aminophylline: 50-400 part; Radix Asparagi: 5000-30000 part; Flos Farfarae: 5000-30000 part; Radix Glycyrrhizae: 5000-15000 part; Chlorphenamine: 2-6 part.
2, the compound medicine of treatment bronchial asthma as claimed in claim is characterized in that: wherein the optimum weight proportioning of each raw material composition is:
Dioxopromethazine: 10 parts; Clenbuterol: 0.04 part; Aminophylline: 200 parts; Radix Asparagi: 14000 parts; Flos Farfarae: 16000 parts; Radix Glycyrrhizae: 8000 parts; Chlorphenamine: 4 parts.
3, the preparation method of the compound medicine of treatment bronchial asthma as claimed in claim 1 or 2, it is characterized in that: the Radix Asparagi of constant weight proportioning, Flos Farfarae, Radix Glycyrrhizae are soaked, decoct and filtering residue after medicinal liquid concentrate, then with the abundant combination dryings of crude drug such as the dioxopromethazine of constant weight proportioning, clenbuterol, aminophylline, chlorphenamine after, the capsule or the tablet that are made into constant weight promptly are prepared from.
CN 01135286 2001-12-14 2001-12-14 Compound medicine for treating bronchial asthma and preparation process Pending CN1358534A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 01135286 CN1358534A (en) 2001-12-14 2001-12-14 Compound medicine for treating bronchial asthma and preparation process

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 01135286 CN1358534A (en) 2001-12-14 2001-12-14 Compound medicine for treating bronchial asthma and preparation process

Publications (1)

Publication Number Publication Date
CN1358534A true CN1358534A (en) 2002-07-17

Family

ID=4673095

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 01135286 Pending CN1358534A (en) 2001-12-14 2001-12-14 Compound medicine for treating bronchial asthma and preparation process

Country Status (1)

Country Link
CN (1) CN1358534A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023953B (en) * 2006-07-24 2010-05-12 南开大学 Composition for treating bronchia asthma
CN103083524A (en) * 2011-10-27 2013-05-08 天津生机集团股份有限公司 Traditional Chinese medicine granules used for treating chicken aspergillosis, and preparation method thereof
CN106377653A (en) * 2016-08-22 2017-02-08 吴斌 A traditional Chinese medicine and western medicine composition for treating bronchial asthma caused by respiratory tract infection and a preparing method thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023953B (en) * 2006-07-24 2010-05-12 南开大学 Composition for treating bronchia asthma
CN103083524A (en) * 2011-10-27 2013-05-08 天津生机集团股份有限公司 Traditional Chinese medicine granules used for treating chicken aspergillosis, and preparation method thereof
CN106377653A (en) * 2016-08-22 2017-02-08 吴斌 A traditional Chinese medicine and western medicine composition for treating bronchial asthma caused by respiratory tract infection and a preparing method thereof

Similar Documents

Publication Publication Date Title
CN102772649A (en) Traditional Chinese medicine composition for treating chronic pharyngitis and preparation method thereof
CN105412858A (en) Syrup and preparation method thereof
CN101041049A (en) Chinese traditional medicine compound took orally for treating chronic bronchitis
CN1742912A (en) Medicine for treating and preventing chronic obstractive pneumonia
CN104116979A (en) Medicinal liquor for treating phthisis and preparation method thereof
CN101884727B (en) Traditional Chinese medicine for treating rhinitis
CN103751349B (en) Traditional Chinese medicine composition for treating rhinitis and preparation method of composition
CN102772650A (en) Traditional Chinese medicine composition for treating chronic pharyngitis and preparation method thereof
CN105250385A (en) Nasal drops for treating infant nasal obstruction
CN1294930C (en) Medication for treating cough caused by inflammation of upper respiratory tract
CN1358534A (en) Compound medicine for treating bronchial asthma and preparation process
CN101129755A (en) Orally taken traditional Chinese medicine composition for treating asthma
CN1410105A (en) Zibei Cough stopping granules and its preparation method
CN105169001A (en) Traditional Chinese medicine composition for treating cough variant asthma in children
CN111494520A (en) Medicine for treating rhinitis and preparation method and application thereof
CN101181448A (en) Oral administration proprietary Chinese medicine for curing facial palsy
CN101199607A (en) Nose kang tea
CN110721303A (en) Traditional Chinese medicine composition for treating allergic rhinitis and application thereof
CN103463517A (en) Medicament for treating asthma
CN108261523A (en) A kind of Chinese medicine composition and method for treating allergic rhinitis
CN114042109B (en) Traditional Chinese medicine composition and patch for inducing resuscitation and stopping nasal discharge, warming yang and strengthening body resistance and preparation method
CN107029058A (en) A kind of Chinese medicine composition for treating chronic pharyngitis
CN106729631A (en) Treat the externally applied spray of intractable skin ulcer
CN101112602B (en) Medicine for treating pharyngitis and method for preparing the same
CN105381351A (en) Traditional Chinese medicine for treating infantile asthma caused by lung qi obstruction

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication